FHIR IG analytics| Package | us.nlm.vsac |
| Resource Type | ValueSet |
| Id | ValueSet-2.16.840.1.113762.1.4.1178.71.json |
| FHIR Version | R4 |
| Source | https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1178.71/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.71 |
| Version | 20220716 |
| Status | active |
| Date | 2022-07-16T01:02:12-04:00 |
| Name | IntoleranceToMRATherapy |
| Title | Intolerance to MRA Therapy |
| Realm | us |
| Authority | hl7 |
| Purpose | (Clinical Focus: The purpose of this value set is to represent concepts of diagnoses of intolerance to mineralocorticoid receptor antagonist (MRA) ingredients.),(Data Element Scope: This value set may use a model element related to Diagnosis.),(Inclusion Criteria: Includes concepts that represent a diagnosis of intolerance to MRA Therapy.),(Exclusion Criteria: No exclusions.) |
No resources found
| CodeSystem | |
| sct | SNOMED codes used in this IG |
No narrative content found in resource
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113762.1.4.1178.71",
"meta": {
"versionId": "6",
"lastUpdated": "2023-12-21T17:43:03.000-05:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "AHA Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2025-03-10"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2022-07-16"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.71",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113762.1.4.1178.71"
}
],
"version": "20220716",
"name": "IntoleranceToMRATherapy",
"title": "Intolerance to MRA Therapy",
"status": "active",
"experimental": false,
"date": "2022-07-16T01:02:12-04:00",
"publisher": "AHA Steward",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of diagnoses of intolerance to mineralocorticoid receptor antagonist (MRA) ingredients.),(Data Element Scope: This value set may use a model element related to Diagnosis.),(Inclusion Criteria: Includes concepts that represent a diagnosis of intolerance to MRA Therapy.),(Exclusion Criteria: No exclusions.)",
"compose": {
"include": [
{
"system": "http://snomed.info/sct",
"concept": [
{
"code": "293472002",
"display": "Spironolactone adverse reaction (disorder)"
},
{
"code": "470681000124105",
"display": "Adverse reaction caused by eplerenone (disorder)"
},
{
"code": "471491000124103",
"display": "Eplerenone not tolerated (situation)"
},
{
"code": "471941000124100",
"display": "Spironolactone not tolerated (situation)"
}
]
}
]
},
"expansion": {
"identifier": "urn:uuid:6d0876f7-fc86-4eac-9424-615130b8b58f",
"timestamp": "2025-05-23T19:08:48-04:00",
"total": 4,
"contains": [
{
"system": "http://snomed.info/sct",
"version": "http://snomed.info/sct/731000124108/version/20250301",
"code": "293472002",
"display": "Spironolactone adverse reaction (disorder)"
},
{
"system": "http://snomed.info/sct",
"version": "http://snomed.info/sct/731000124108/version/20250301",
"code": "470681000124105",
"display": "Adverse reaction caused by eplerenone (disorder)"
},
{
"system": "http://snomed.info/sct",
"version": "http://snomed.info/sct/731000124108/version/20250301",
"code": "471491000124103",
"display": "Eplerenone not tolerated (situation)"
},
{
"system": "http://snomed.info/sct",
"version": "http://snomed.info/sct/731000124108/version/20250301",
"code": "471941000124100",
"display": "Spironolactone not tolerated (situation)"
}
]
}
}